Arix Bioscience Sustainability Profile
Arix Bioscience, a leading life sciences company headquartered in Great Britain, focuses on advancing innovative therapies in the biotechnology sector. Founded in 2013, Arix has established itself as a key player in the industry, with a strong emphasis on developing and commercialising breakthrough treatments across various therapeutic areas, including oncology and rare diseases. The company is renowned for its unique approach to building and supporting a diverse portfolio of life science companies, leveraging its deep expertise and extensive network. Arix Bioscience's commitment to fostering innovation has positioned it as a prominent venture capital firm, recognised for its strategic investments and successful partnerships. With a robust pipeline of core products and a reputation for excellence, Arix continues to make significant strides in transforming healthcare and improving patient outcomes.
DitchCarbon Score
How does Arix Bioscience's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Arix Bioscience's score of 30 is higher than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Arix Bioscience's reported carbon emissions
In 2022, Arix Bioscience reported total carbon emissions of approximately 13,780 kg CO2e, comprising 3,680 kg CO2e from Scope 1, 8,890 kg CO2e from Scope 2 (market-based), and 5,210 kg CO2e from Scope 3 emissions. This reflects a notable decrease from 2021, where total emissions were about 12,760 kg CO2e, with Scope 1 emissions at 4,860 kg CO2e, Scope 2 (market-based) at 2,940 kg CO2e, and Scope 3 at 2,900 kg CO2e. Arix Bioscience has not set specific reduction targets or initiatives as part of their climate commitments, nor do they participate in initiatives such as the Science Based Targets initiative (SBTi). The company has disclosed emissions data for all three scopes, indicating a comprehensive approach to understanding their carbon footprint. The emissions data is not cascaded from any parent organization, and all figures are reported directly by Arix Bioscience plc. The company continues to monitor and report its emissions, contributing to transparency in its climate impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | |
|---|---|---|---|
| Scope 1 | 5,020 | 0,000 | 0,000 |
| Scope 2 | 90 | 0,000 | 0,000 |
| Scope 3 | - | 0,000 | 0,000 |
How Carbon Intensive is Arix Bioscience's Industry?
How Carbon Intensive is Arix Bioscience's Location?
Arix Bioscience's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Arix Bioscience has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
